Resistant Nonalcoholic Fatty Liver Disease Amelioration With Rosuvastatin and Pioglitazone Combination Therapy in a Patient With Metabolic Syndrome

Annals of Pharmacotherapy

Volumn 48, Issue 1, 2014, Pages 137-141

  Riche, Daniel M ^a,b   Fleming, Joshua W ^a   Malinowski, Scott S ^a   Black, Catherine A ^c   Miller, Kristen H ^b   Wofford, Marion R ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c Walgreen's   (United States)

Author keywords

antioxidants; fatty liver; NAFLD; pioglitazone; statin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; FISH OIL; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; INSULIN GLARGINE; METFORMIN; MEVINOLIN; MULTIVITAMIN; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; HEADACHE; HUMAN; HYPERTENSION; LIVER SIZE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; WEIGHT GAIN;

ANTIOXIDANTS; FATTY LIVER; NAFLD; PIOGLITAZONE; STATIN;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY LIVER; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PYRIMIDINES; SULFONAMIDES; THIAZOLIDINEDIONES;

EID: 84892880355     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013507239     Document Type: Article

References (20)

1. Lazo M,Clark JM.The epidemiology of nonalcoholic fatty liver disease: a global perspective.Semin Liver Dis. 2008;28:339-350.
2. Ekstedt M,Franzen LE,Mathiesen UL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatolog. 2006;44:865-873.
3. Targher G,Day CP,Bonora E.Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.N Engl J Med. 2010;363:1341-1350.
4. Ratziu V,Bellentani S,Cortez-Pinto H,Day C,Marchesini G.A position statement on NAFLD/NASH based on the EASL 2009 special conference.J Hepatol. 2010;53:372-384.
5. Malinowski SS,Byrd JS,Bell AM,Wofford MR,Riche DM.Pharmacologic therapy for nonalcoholic fatty liver disease in adults.Pharmacotherapy. 2013;33:223-242.
6. Cohen DE,Anania FA,Chalasani N.National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists.Am J Cardiol. 2006;97:77C-81C.
7. Bhatia LS,Curzen NP,Calder PC,Byrne CD.Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?.Eur Heart J. 2012;33:1190-1200.
8. Athyros VG,Mikhailidis DP,Didangelos TP, et al.Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.Curr Med Res Opin. 2006;22:873-883.
9. Foster T,Budoff MJ,Saab S,Ahmadi N,Gordon C,Guerci AD.Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study Randomized Clinical Trial.Am J Gastroenterol. 2011;106:71-77.
10. Roldan-Valadez E,Favila R,Martinez-Lopez M,Uribe M,Mendez-Sanchez N.Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease.Ann Hepatol. 2008;7:212-220.
11. Enjoji M,Kotoh K,Kato M, et al.Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.Int J Mol Med. 2008;22:521-527.
12. Sanyal AJ,Chalasani N,Kowdley KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.N Engl J Med. 2010;362:1675-1685.
13. Chalasani N,Aljadhey H,Kesterson J,Murray MD,Hall SD.Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.Gastroenterology. 2004;126:1287-1292.
14. Vuppalanchi R,Teal E,Chalasani N.Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.Am J Med Sci. 2005;329:62-65.
15. Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/drugs/DrugSafety/ucm293101.htm. Accessed May 15, 2012.
16. Gomez-Dominguez E,Gisbert JP,Moreno-Monteagudo JA,Garcia-Buey L,Moreno-Otero R.A pilot study of atorvastatin treatment in dyslipidemia, non-alcoholic fatty liver patients.Aliment Pharmacol Ther. 2006;23:1643-1647.
17. Nelson A,Torres DM,Morgan AE,Fincke C,Harrison SA.A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial.J Clin Gastroenterol. 2009;43:990-994.
18. Antonopoulos S,Mikros S,Mylonopoulou M,Kokkoris S,Giannoulis G.Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.Atherosclerosis. 2006;184:233-234.
19. Belfort R,Harrison SA,Brown K, et al.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med. 2006;355:2297-2307.
20. Lutchman G,Modi A,Kleiner DE, et al.The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.Hepatology. 2007;46:424-429.